Sol J. Barer, Ph.D.
Chairman of the Board of Directors, Hackensack Meridian Health Center for Discovery and Innovation
Dr. Sol J. Barer, Ph.D. was named Chairman of the Board of Directors for the new Hackensack Meridian Health Center for Discovery and Innovation in June 2018. Dr. Barer currently serves as Chairman of the Board of Directors of Teva Pharmaceuticals. He is Managing Partner at SJ Barer Consulting and serves as an advisor to the Israel Biotech Fund. From 1987 to 2011, he served in top leadership roles at Celgene Corporation, including as Executive Chairman from 2010 to 2011, Chairman and CEO from 2007 to 2010, CEO from 2006 to 2010, President and Chief Operating Officer from 1994 to 2006 and President from 1993 to 1994. Prior to that, he was a founder of the biotechnology group at the chemical company Celanese Corporation, which was later spun off as Celgene. Dr. Barer serves on the board of directors of Contrafect as lead director. He previously served on the board of Aegerion Pharmaceuticals from 2011 to 2016, on the board of Amicus Therapeutics from 2009 to February 2017 and as Chairman of the Board of InspireMD from 2011 to June 2017. Dr. Barer is Chairman of the Board of Edge Therapeutics , Aevi Genomics (formerly Medgenics) and Centrexion Therapeutics.
Andrew L. Pecora, M.D., FACP CPE
Chief Innovation Officer and Vice President of Cancer Services, Hackensack Meridian Health
Over the past 25 years, Dr. Pecora has transformed medicine by developing the John Theurer Cancer Center at Hackensack University Medical Center, into one of the nation’s top cancer centers, where he currently serves as Chief Innovation Officer and Vice President of Cancer Services. Dr. Pecora is one of the world’s foremost experts in blood and marrow stem cell transplantation, cellular medicine, and immunology research. He is actively involved in clinical evaluation of novel antineoplastic agents including cancer vaccines and targeted therapies. He is also involved in laboratory and clinical development of engineered blood and marrow stem cell grafts for autologous and allogeneic transplantation, as well as cell therapy for regenerative medicine. As an entrepreneur, he founded Amorcyte, LLC in 2005 and is the Founder and Executive Chairman of COTA, Inc.
David S. Perlin, Ph.D.
Chief Scientific Officer and Senior Vice President, Hackensack Meridian Health Center for Discovery and Innovation
David Perlin, PhD is the founding Chief Scientific Officer and Senior Vice President for the Hackensack Meridian Health Center for Discovery and Innovation. He is a highly accomplished senior administrator and biomedical researcher focused on combatting opportunistic infections in cancer, transplant and other high risk patients. Dr. Perlin was most recently Executive Director and Professor at the Rutgers University, New Jersey Medical School where he led the 77-year old Public Health Research Institute (PHRI), a center for the study of infectious diseases. In the past 12 years, he helped PHRI attract more than $230 million in grant support and develop a robust portfolio of patents and licenses resulting in FDA-approved products. Dr. Perlin’s research emphasizes studies to diagnose and overcome drug resistant fungal and bacterial infections in high-risk patients, and he is widely regarded as a global leader in antifungal drug resistance, molecular diagnostics, and antifungal drug development. He has published more than 250 papers and book chapters, and has co-authored two books. His laboratory is supported by multiple grants from the NIH, CDC, Pharma and biopharma sectors.
David Siegel, M.D., Ph.D.
Founding Director of the Institute for Multiple Myeloma, Hackensack Meridian Health Center for Discovery and Innovation; Chief of the Multiple Myeloma Division, John Theurer Cancer Center
David S. Siegel, MD, PhD, is one of the nation’s foremost authorities on multiple myeloma (a blood cancer) and is founding Director of the Multiple Myeloma Institute. His research focuses on multiple myeloma, Waldenstrom’s macroglobulinemia, and AL amyloidosis. He has served as the lead investigator of the pivotal phase IIb study that led to the U.S. Food and Drug Administration’s approval of Kyprolis (carfilzomib) for recurrent multiple myeloma. Dr. Siegel helped bring Velcade (bortezomib) to multiple myeloma patients through his clinical trials showing that this medication slows and halts the progression of multiple myeloma. He has been involved in clinical trials that led to the approval of Thalomid (thalidomide), Revlimid (lenalidomide), Pomalyst (pomalidomide), Ninlaro (Ixazomib), Empliciti (elotuzumab), and Farydak (panobinostat). Dr. Siegel has led the John Theurer Cancer Center’s program to offer CAR T-cell therapy to patients with multiple myeloma. Finally, he is a member of the Multiple Myeloma Research Consortium Steering Committee, which promotes novel, cutting-edge treatments for patients afflicted by multiple myeloma.
Andre Goy, M.D., M.S
Chair and Director, Chief of Lymphoma and Director of Clinical and Translational Cancer Research, John Theurer Cancer Center
Andre Goy, M.D., M.S., is Chairman and Director of John Theurer Cancer Center (JTCC) at Hackensack University Medical Center. As Chief of the Division of Lymphoma, he leads New Jersey’s largest program for lymphoma treatment and research. Dr. Goy has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris, and The Pasteur Institute. Widely known for his work in mantle cell lymphoma, Dr. Goy was the lead investigator in the development of three FDA-approved drugs for this disease: bortezomib, lenalidomide, and ibrutinib. He participated in the pilot study of rituximab, which has improved the treatment of B-cell lymphoma, leukemia, and autoimmune disorders. In his current research, Dr. Goy is assessing biomarkers for lymphoma as well as novel anticancer agents, drug combinations, and non-chemotherapy options. Under Dr. Goy’s direction, JTCC became one of the few sites in the country offering chimeric antigen receptor (CAR) T-cell therapy—a highly promising immunotherapy for certain blood cancers.